Ascentage Pharma Group International (AAPG)vsargenx NV ADR (ARGX)
AAPG
Ascentage Pharma Group International
$15.43
+1.98%
HEALTHCARE · Cap: $1.40B
ARGX
argenx NV ADR
$927.21
+3.63%
HEALTHCARE · Cap: $58.31B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 821% more annual revenue ($5.92B vs $642.63M). ARGX leads profitability with a 31.7% profit margin vs -228.5%. ARGX earns a higher WallStSmart Score of 73/100 (B).
AAPG
Avoid25
out of 100
Grade: F
ARGX
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AAPG.
Margin of Safety
+67.3%
Fair Value
$2552.01
Current Price
$927.21
$1624.80 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 29.3% year-over-year
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 36.3%
Revenue surging 52.1% year-over-year
Earnings expanding 50.6% YoY
Safe zone — low bankruptcy risk
Areas to Watch
Trading at 17.3x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 172.3x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : AAPG
The strongest argument for AAPG centers on Revenue Growth. Revenue growth of 29.3% demonstrates continued momentum.
Bull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 31.7% and operating margin at 36.3%. Revenue growth of 52.1% demonstrates continued momentum.
Bear Case : AAPG
The primary concerns for AAPG are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 3.76 is elevated, increasing financial risk.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Key Dynamics to Monitor
AAPG carries more volatility with a beta of 0.66 — expect wider price swings.
ARGX is growing revenue faster at 52.1% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 25/100), backed by strong 31.7% margins and 52.1% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ascentage Pharma Group International
HEALTHCARE · BIOTECHNOLOGY · USA
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company is headquartered in Suzhou, China.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?